At the recent SEC meeting for endocrinology and metabolism, the expert panel reviewed the proposal along with the ...

The study tested the effects of balcinrenone/dapagliflozin, a combination drug, in different conditions: fasted, fed, and with the P-gp inhibitor quinidine. The goal was to understand how these ...

A new study published in the European Journal of Medical Research revealed that dapagliflozin, a sodium-glucose ...

Results from clinical trials show that patients receiving dapagliflozin in combination with other OADs had A1C reductions in the range of —0.4% to –1.2% at 1 year. 6,7,22,23 Our study found ...

Dapagliflozin is a novel, selective, sodium glucose co-transporter 2 (SGLT2) inhibitor, currently being evaluated in Phase 3 trials as a once-daily oral therapy for the treatment of type 2 diabetes.

Dapagliflozin may exert a protective effect on kidney function in patients with chronic kidney disease associated with autosomal dominant polycystic kidney disease (ADPKD) when used in conjunction ...

Dapagliflozin, an investigational compound, is a potential first-in-class sodium-glucose cotransporter-2 (SGLT2) inhibitor currently in Phase 3 trials under joint development by Bristol-Myers ...

Kato E, et al. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus based on ejection fraction [published online March 18, 2019]. Circulation. Verma S, McMurray JJV.

Dapagliflozin was well tolerated among patients with an eGFR of less than 60 mL/minute per 1.73² and among those with an eGFR of greater than or equal to 60 mL/minute per 1.73².

The researchers found that 53% of the 78 participants in the dapagliflozin group and 30% of the 76 participants in the placebo group had MASH improvement without worsening of fibrosis (risk ratio ...

The study tested the effects of balcinrenone/dapagliflozin, a drug combination, both in fed and fasted states, and with the addition of quinidine, a P-gp inhibitor. The purpose is to understand how ...